ClinVar Miner

Submissions for variant NM_004168.4(SDHA):c.151-2A>G

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV003086856 SCV003483076 likely pathogenic Mitochondrial complex II deficiency, nuclear type 1; Paragangliomas 5 2024-06-19 criteria provided, single submitter clinical testing This sequence change affects an acceptor splice site in intron 2 of the SDHA gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in SDHA are known to be pathogenic (PMID: 22974104, 24781757). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with benign sporadic primary hyperparathyroidism (PMID: 35586626). ClinVar contains an entry for this variant (Variation ID: 2168252). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Myriad Genetics, Inc. RCV003455712 SCV004189651 likely pathogenic Paragangliomas 5 2023-11-06 criteria provided, single submitter clinical testing This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function.
Ambry Genetics RCV004073222 SCV005021371 likely pathogenic Hereditary cancer-predisposing syndrome 2023-11-13 criteria provided, single submitter clinical testing The c.151-2A>G intronic variant results from an A to G substitution two nucleotides upstream from coding exon 3 in the SDHA gene. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and may result in the creation or strengthening of a novel splice acceptor site. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). Another alteration impacting the same acceptor site (c.151-1G>C) has been shown to have a similar impact on splicing and observed in at least one individual with a personal and/or family history that is consistent with SDHA-related disease (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence to date, this variant is likely to be pathogenic.
GeneDx RCV004725525 SCV005332772 likely pathogenic not provided 2024-03-13 criteria provided, single submitter clinical testing Observed in an individual with hyperparathyroidism (PMID: 35586626); Canonical splice site variant predicted to result in an in-frame loss of the adjacent exon in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 35586626)

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.